MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds†) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego's Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Future Labs is part of Apimeds' ai² innovation. ...